Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07171112 · ClinicalTrials.gov registry record · Phase 2
Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis
A Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis, sponsored by Mayo Clinic.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 45
- Enrollment target
- 1
- Study location
NCT07171112 is a Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis that is actively recruiting participants, run by Mayo Clinic. The registered enrollment target is 45 participants, below the 387-participant average among 6 other Smoking (Tobacco) Addiction trials with a reported enrollment target (88% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07171112, a Phase 2 study of Smoking (Tobacco) Addiction and Recurrent Acute Pancreatitis, is actively recruiting participants, sponsored by Mayo Clinic.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 45 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoking, at its standard dose. For those who are unable to stop smoking after 6 weeks of treatment, they will be randomly selected to either 1) increase their dose of varenicline, 2) combine varenicline with bupropion (another medication that helps with smoking cessation) or continue on the standard dose of varenicline. At the end of 12 weeks of treatment, participants will be asked if they have stopped smoking with confirmation done by measuring carbon monoxide levels in their breath.
Conditions Studied
Interventions
- DRUG Standard Varenicline Dosing (1 mg BID)
- DRUG Bupropion 150 mg twice daily
- DRUG Increased Varenicline Dosing (1mg TID)
Study Locations (1)
Minnesota
- Mayo Clinic - Rochester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 45 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2028-10-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07171112
The ClinicalTrials.gov registry entry for NCT07171112 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 45 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 387-participant average among 6 other Smoking (Tobacco) Addiction trials with a reported enrollment target (88% lower). The listed sponsor is Mayo Clinic, which has 2,844 total studies on file at ClinicalTrials.gov.
The record links to 4 conditions, with Smoking (Tobacco) Addiction appearing as the primary indexed condition, and to 3 interventions - of which Standard Varenicline Dosing (1 mg BID) is the first listed.
NCT07171112 reports 1 study location spanning 1 distinct geographic area - top geographies include Minnesota.
Frequently Asked Questions
What is clinical trial NCT07171112 about?
NCT07171112 is a clinical study titled "Smoking Cessation Trial in Recurrent Acute Pancreatitis and Chronic Pancreatitis". The purpose of this research is to assess the effectiveness of two treatment strategies for smoking cessation in patients with acute recurrent pancreatitis or chronic pancreatitis who smoke cigarettes. All participants will receive varenicline, a commonly used medication that helps people stop smoki...
What is the current status of trial NCT07171112?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 45 participants. The study started on 2025-11-06. Estimated completion is 2028-10-01.
What conditions does trial NCT07171112 study?
This clinical trial studies the following conditions: Smoking (Tobacco) Addiction, Recurrent Acute Pancreatitis, Pancreatitis, Chronic, Pancreatitis, Acute.
What interventions are being tested in trial NCT07171112?
The interventions under investigation include: Standard Varenicline Dosing (1 mg BID) (DRUG), Bupropion 150 mg twice daily (DRUG), Increased Varenicline Dosing (1mg TID) (DRUG).
Who is sponsoring clinical trial NCT07171112?
This trial is sponsored by Mayo Clinic, which has 2,844 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07171112 being conducted?
This trial has 1 study location across Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Smoking (Tobacco) Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Oklahoma Study of Native American Pain Risk IV: Smoking Cessation and Pain
RECRUITING · NA
-
ACT Lung Health Intervention: Phase Two
RECRUITING · NA
-
A Study Evaluating the Use of an Indoor Air Quality Monitor to Promote a Smoke-free Home
RECRUITING · NA
-
Addiction Potential of Very Low Nicotine Filtered Little Cigars
RECRUITING · Phase 4
-
Helping Poor Smokers Quit
COMPLETED · NA
-
Addiction and Behavior Related to Menthol Cigarette Substitutes
COMPLETED · NA
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.